Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer

Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive... Letters Corresponding Author: Jinbo Yue, MD, Department of Radiation Oncology, Questions About a Clinical Trial Evaluating Shandong Cancer Hospital and Institute, Shandong Cancer Hospital affiliated the Addition of Cetuximab to Definitive to Shandong University, 440 Jinyan Rd, Jinan 250117, Shandong, China Chemoradiation Therapy With Paclitaxel and (yuejinbo@hotmail.com). Cisplatin for Patients With Esophageal Cancer Published Online: March 29, 2018. doi:10.1001/jamaoncol.2018.0228 To the Editor We read with interest the article by Suntharalingam Conflict of Interest Disclosures: None reported. et al demonstrating that the addition of cetuximab to concur- 1. Suntharalingam M, Winter K, Ilson D, et al. Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal rent chemoradiation therapy did not improve overall sur- cancer: the NRG Oncology RTOG 0436 phase 3 randomized clinical trial. vival in the nonoperative treatment of patients with esopha- JAMA Oncol. 2017;3(11):1520-1528. geal cancer. Although the study stratified patients according 2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer to tumor histologic type, it was not powered to assess with cer- statistics. CA Cancer J Clin. 2011;61(2):69-90. tainty the benefit of cetuximab therapy in each of the 2 main 3. Bonner JA, Harari http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer

JAMA Oncology , Volume 4 (6) – Jun 29, 2018

Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer

Abstract

Letters Corresponding Author: Jinbo Yue, MD, Department of Radiation Oncology, Questions About a Clinical Trial Evaluating Shandong Cancer Hospital and Institute, Shandong Cancer Hospital affiliated the Addition of Cetuximab to Definitive to Shandong University, 440 Jinyan Rd, Jinan 250117, Shandong, China Chemoradiation Therapy With Paclitaxel and (yuejinbo@hotmail.com). Cisplatin for Patients With Esophageal Cancer Published Online: March 29, 2018. doi:10.1001/jamaoncol.2018.0228 To the...
Loading next page...
 
/lp/american-medical-association/questions-about-a-clinical-trial-evaluating-the-addition-of-cetuximab-pC73h9Q10K

References (5)

Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2018.0228
Publisher site
See Article on Publisher Site

Abstract

Letters Corresponding Author: Jinbo Yue, MD, Department of Radiation Oncology, Questions About a Clinical Trial Evaluating Shandong Cancer Hospital and Institute, Shandong Cancer Hospital affiliated the Addition of Cetuximab to Definitive to Shandong University, 440 Jinyan Rd, Jinan 250117, Shandong, China Chemoradiation Therapy With Paclitaxel and (yuejinbo@hotmail.com). Cisplatin for Patients With Esophageal Cancer Published Online: March 29, 2018. doi:10.1001/jamaoncol.2018.0228 To the Editor We read with interest the article by Suntharalingam Conflict of Interest Disclosures: None reported. et al demonstrating that the addition of cetuximab to concur- 1. Suntharalingam M, Winter K, Ilson D, et al. Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal rent chemoradiation therapy did not improve overall sur- cancer: the NRG Oncology RTOG 0436 phase 3 randomized clinical trial. vival in the nonoperative treatment of patients with esopha- JAMA Oncol. 2017;3(11):1520-1528. geal cancer. Although the study stratified patients according 2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer to tumor histologic type, it was not powered to assess with cer- statistics. CA Cancer J Clin. 2011;61(2):69-90. tainty the benefit of cetuximab therapy in each of the 2 main 3. Bonner JA, Harari

Journal

JAMA OncologyAmerican Medical Association

Published: Jun 29, 2018

There are no references for this article.